Delivery Order SPE2DB24D2109-SPE2DB25FHXLM
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp, the prime contractor, on August 7, 2025, for the supply of Vyvanse 40 mg capsules (100 count). This competitively awarded, non-set-aside contract carries a ceiling value of $1,161.44 with firm fixed pricing and a completion date of August 8, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order represents a routine pharmaceutical...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Vyvanse 40 mg capsules (100 count) valued at $1,017.86 with a firm fixed price structure. The award was made on September 8, 2025, with an ultimate completion date of September 9, 2025, and no set-aside designation was applied, indicating the contract was competitively awarded. The point of performance is located in Conshohocken, Pennsylvania, where AmerisourceBergen Drug Corp maintains...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 19, 2025, for the supply of Vyvanse 40 mg capsules in a quantity of 100 units. The contract is valued at $2,255.82 with a firm fixed price structure and a completion date of August 20, 2025. This non-set-aside award represents a routine pharmaceutical procurement through the DLA's medical supply chain, with performance to be executed from the contractor's corporate headquarters location in...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on September 3, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a contract value of $2,971.21. This competitively awarded, firm fixed-price delivery order is set to be completed by September 4, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a firm fixed-price delivery order to AmerisourceBergen Drug Corp on July 24, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a ceiling value of $5,644.36. The order is set to be completed by July 25, 2025, and will be performed at the awardee's corporate office location in Conshohocken, Pennsylvania. This non-set-aside award represents a competitive procurement action under AmerisourceBergen's larger Indefinite Delivery Contract with DLA...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 7, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) with a ceiling value of $5,486.46. This is a firm fixed-price delivery order with no set-aside designation, reflecting a competitive award to this major pharmaceutical distributor. The order is set for ultimate completion on August 8, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania location. This...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on August 22, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $2,354.62. This is a non-set-aside competitive award with an ultimate completion date of August 25, 2025, and performance will be executed from the awardee's Conshohocken, Pennsylvania location. The delivery order is a child contract under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $3,076.43 delivery order to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count) on June 24, 2025, with an ultimate completion date of June 25, 2025. This firm fixed-price, non-set-aside contract represents a small-value pharmaceutical delivery supporting federal medical procurement needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical vendor for military...
- The Defense Logistics Agency awarded a delivery order valued at $1,544.99 to AmerisourceBergen Drug Corp for Vyvanse 40 mg capsules (100-count units) on July 29, 2025, with completion targeted for July 30, 2025. This firm fixed-price delivery order represents a non-competitive set-aside award issued under a larger indefinite delivery contract. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on June 30, 2025, for the supply of Vyvanse 50 mg capsules (100 count) with a ceiling value of $2,193.53. This firm fixed-price delivery order is set to be completed by July 1, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The award represents a competitive, non-set-aside procurement conducted through the federal contracting system. This delivery...
- SPE2DB24D2109Indefinite Delivery Contract
- SPE2DB24D2109-SPE2DB25FHXLMDelivery Order
The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order on July 18, 2025, for the supply of Vyvanse 40 mg capsules (100-count units) under a firm fixed-price contract valued at $5,184.69. The order, which is set to be completed by July 21, 2025, represents a routine pharmaceutical procurement to support military healthcare operations. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), a $999,999,999 prime vendor agreement that runs through December 2026 and provides global pharmaceutical support for military health systems worldwide. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical supply vendor. The award was competitively awarded with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal procurement standards through open competition. The company's extensive contract portfolio with DLA encompasses a broad range of pharmaceutical products and medical supplies, including specialty medications, brand-name and generic drugs, vaccines, and medical devices across multiple therapeutic domains to support the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $5.2k | 7/18/25 |